You could be excused for thinking biotech is entering the summer doldrums. But those who took a few days off the grid will discover they’ve missed quite a bit. Money is continuing to flow like a river after a rainstorm: The median deal size in biopharma is now $42.8 million–almost triple where it was in 2013, according to a mid-year report by Silicon Valley Bank.
